November 28, 2018 / 7:17 PM / 16 days ago

Astellas Pharma gets U.S. nod for blood cancer treatment

Nov 28 (Reuters) - Japan's Astellas Pharma Inc on Wednesday received approval from the U.S. Food and Drug Administration for its blood cancer treatment, according to the regulator's website bit.ly/2SjB8CL.

The oral drug, Xospata, was approved to treat patients with acute myeloid leukemia (AML) with a FLT3 mutation, whose cancer has relapsed or proved treatment-resistant. (Reporting by Tamara Mathias and Manas Mishra in Bengaluru; Editing by Shailesh Kuber)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below